DDInter219 DDInter1376
A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Bleomycin {u} (Compound) treats {v} (Disease) melanoma
Bleomycin {u} (Compound) binds {v} (Gene) BLMH
Bleomycin {u} (Compound) causes {v} (Side Effect) Hypomagnesaemia
Bleomycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Bleomycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Bleomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alefacept
Bleomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofarabine
Bleomycin {u} may lead to a major life threatening interaction when taken with {v} Golimumab
Bleomycin {u} may lead to a major life threatening interaction when taken with {v} Natalizumab
Bleomycin (Compound) treats melanoma (Disease)
Bleomycin (Compound) binds BLMH (Gene)
Bleomycin (Compound) causes Hypomagnesaemia (Side Effect)
Bleomycin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Bleomycin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Alefacept
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine
Bleomycin may lead to a major life threatening interaction when taken with Golimumab
Bleomycin may lead to a major life threatening interaction when taken with Natalizumab